Readily isolated bispecific antibodies with native immunoglobulin format

Patent metadata

Field	Value
Publication number	US-9982013-B2
Application number	US-201615058026-A
Country	US
Kind code	B2
Filing date	Mar 1, 2016
Priority date	Jun 26, 2009
Publication date	May 29, 2018
Grant date	May 29, 2018

Abstract

A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

First claim

What is claimed is:

1. A method for isolating a bispecific antigen-binding protein, comprising:
contacting a disrupted cell or a mixture of antigen-binding proteins with a Protein A affinity support; and
eluting a bispecific antigen-binding protein with a pH gradient, in the presence of an ionic modifier;
wherein the bispecific antigen-binding protein comprises a heterodimeric IgG CH3 region comprising a first and a second IgG CH3 domain, each with a different affinity to Protein A.

2. The method of claim 1 , wherein the ionic modifier is a salt selected from the group consisting of beryllium acetate, lithium acetate, sodium acetate, potassium acetate, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium chloride, sodium chloride, potassium chloride, cesium chloride, magnesium chloride, sodium fluoride, potassium fluoride, sodium nitrate, potassium nitrate, calcium nitrate, sodium phosphate, potassium phosphate, calcium sulfate, magnesium sulfate, an alkaline metal salt, an alkaline earth metal salt, and a halogen salt.

3. The method of claim 1 , wherein the ionic modifier is present at a concentration of about 0.15 to about 0.5 molar.

4. The method of claim 3 , wherein the ionic modifier is NaCl and it is present at a concentration of at least about 150 mM.

5. The method of claim 1 , wherein the ionic modifier is present at a concentration of about 0.5 to about 1.0 molar.

6. The method of claim 1 , wherein the pH gradient comprises a gradient from about pH 4.0 to about pH 4.4.

7. The method of claim 1 , wherein the pH gradient is a linear gradient.

8. The method of claim 1 , wherein the pH gradient is a step gradient.

9. The method of claim 1 , wherein the bispecific antigen-binding protein elutes at a pH between about 3.9 to about 4.4.

10. The method of claim 8 , wherein the bispecific antigen-binding protein elutes at a pH of about 4.2.

11. The method of claim 1 , wherein the mixture is culture medium.

12. The method of claim 1 , wherein the bispecific antigen-binding protein comprising the heterodimeric IgG CH3 region elutes in one or more fractions comprising less than about 1% of total protein by weight antibodies comprising a homodimeric IgG CH3 region that comprises CH3 domains with the same affinities with respect to Protein A.

13. The method of claim 1 , wherein the second IgG CH3 region comprises a modification that reduces or eliminates binding of the second CH3 region to Protein A.

14. The method of claim 13 , wherein the first and second IgG CH3 domains are each a human IgG heavy chain CH3 domain selected from the group consisting of a human IgG1 heavy chain CH3 domain, a human IgG2 heavy chain CH3 domain, and a human IgG4 heavy chain CH3 domain.

15. The method of claim 14 , wherein the modification is selected from the group consisting of (a) 95R, and (b) 95R and 96F in the IMGT exon numbering system, or (a′) 435R, and (b′) 435R and 436F in the EU numbering system.

16. The method of claim 15 , wherein the second IgG CH3 domain is
a human IgG1 CH3 domain and further comprises one to five modifications selected from the group consisting of 16E, 18M, 44S, 52N, 57M, and 82I in the IMGT exon numbering system, or 356E, 358M, 384S, 392N, 397M, and 422I in the EU numbering system,
a human IgG2 CH3 domain and further comprising one or two modifications selected from the group consisting of 44S, 52N, 82I in the IMGT exon numbering system, or 348S, 392N and 422I in the EU numbering system, or
a human IgG4 CH3 domain and further comprising one to seven modifications selected from the group consisting of 15R, 44S, 52N, 57M, 69K, 79Q and 82I in the IMGT exon numbering system or 355R, 384S, 392N, 397M, 409K, 419Q and 422I in the EU numbering system.

17. The method of claim 15 , wherein the second IgG CH3 domain is a human IgG4 CH3 domain and further comprises the modification 105P in the IGMT exon numbering system or 445P in the EU numbering system.

18. The method of claim 1 , wherein the first and second IgG CH3 domains are the same isotype.

19. The method of claim 1 , wherein the heterodimeric CH3 regions of the bispecific antigen-binding protein is non-immunogenic or substantially non-immunogenic in a human.

20. The method of claim 1 , wherein the bispecific antigen-binding protein comprises two light chains that are the same.

21. The method of claim 1 , wherein the bispecific antigen-binding protein displays a pharmocokinetic profile equivalent to the same bispecific antigen-binding protein having a homodimeric IgG CH3 region.

22. The method of claim 1 , wherein the Protein A affinity support is a Protein A column.

Assignees

• Regeneron Pharma

Inventors

• Davis Samuel
• Smith Eric
• Macdonald Douglas
• Olson Kara Louise

Classifications

• C07K1/22 Primary

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K2317/526

  CH3 domain · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/461

  Igs containing Ig-regions, -domains or -residues form different species · CPC title